Opus Genetics Stock Discussion

$Opus Genetics (IRD.US)$
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Thursday, 19th December at 8:00 am
Agreement Reached on Primary Endpoint and Phase 3 Trial Design
Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering
FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the tre...

$Fresh2(Delisted) (FRES.US)$ $Opus Genetics (IRD.US)$ $Sangamo Therapeutics (SGMO.US)$ $Kindly MD (KDLY.US)$ $Edesa Biotech (EDSA.US)$ $Sadot (SDOT.US)$ $Lazydays (GORV.US)$ $Zeo Energy (ZEO.US)$ $Hall Of Fame Resort & Entertainment (HOFV.US)$ $Nauticus Robotics (KITT.US)$ $KORE Group (KORE.US)$ $Digital Brands Group (DBGI.US)$ $Hoth Therapeutics (HOTH.US)$ $Tonix Pharmaceuticals (TNXP.US)$
📊⚡️📊